BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26293198)

  • 21. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of antiemetic management in terminal illness.
    Lichter I
    J Palliat Care; 1993; 9(2):19-21. PubMed ID: 8397302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
    Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of drug-induced nausea and vomiting].
    Herrstedt J; Dombernowsky P
    Ugeskr Laeger; 1994 Jan; 156(4):453-60. PubMed ID: 8140660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting.
    Chu CC; Hsing CH; Shieh JP; Chien CC; Ho CM; Wang JJ
    Eur J Pharmacol; 2014 Jan; 722():48-54. PubMed ID: 24184695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Postoperative nausea and vomiting].
    Raeder JC
    Tidsskr Nor Laegeforen; 1994 May; 114(13):1526-30. PubMed ID: 8079248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer.
    Mystakidou K; Befon S; Liossi C; Vlachos L
    Cancer; 1998 Sep; 83(6):1214-23. PubMed ID: 9740088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE
    J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacological profile of intravenous amisulpride for the treatment of postoperative nausea and vomiting.
    Fox G; Kranke P
    Expert Rev Clin Pharmacol; 2020 Apr; 13(4):331-340. PubMed ID: 32245336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.
    Hesketh PJ
    Oncology (Williston Park); 2004 Sep; 18(10 Suppl 6):9-14. PubMed ID: 15510975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical selection of antiemetics.
    Flake ZA; Scalley RD; Bailey AG
    Am Fam Physician; 2004 Mar; 69(5):1169-74. PubMed ID: 15023018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.